Drug General Information |
Drug ID |
D0GH2C
|
Former ID |
DCL001005
|
Drug Name |
Sulfasalizine
|
Drug Type |
Small molecular drug
|
Indication |
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06]
|
Phase 3 |
[1]
|
Company |
Pfizer
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C18H14N4O5S
|
Canonical SMILES |
C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)NN=C3C=CC(=O)C(=C3)<br />C(=O)O
|
InChI |
1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,20H,(H,19,22)(H,24,25)/b21-13-
|
InChIKey |
OQANPHBRHBJGNZ-BKUYFWCQSA-N
|
CAS Number |
CAS 599-79-1
|
PubChem Compound ID |
|
PubChem Substance ID |
9524, 452205, 7847514, 7890377, 10321791, 11112423, 17389737, 26747277, 26747278, 39383787, 46391376, 46505451, 48414442, 48416584, 48424062, 48425604, 49698537, 50105482, 50105483, 53789773, 57361929, 78341122, 85147460, 85164696, 85174423, 85787939, 87560165, 92125445, 93166319, 103914276, 103994509, 104134816, 114147521, 117607242, 124890162, 124890163, 134337474, 134339436, 134976371, 135692179, 139618183, 144204588, 144208437, 144210859, 160964137, 164788662, 170464716, 172386498, 175267319, 179038496
|
ChEBI ID |
ChEBI:9334
|
SuperDrug ATC ID |
A07EC01
|
SuperDrug CAS ID |
cas=000599791
|
Target and Pathway |
Target(s) |
Nuclear factor NF-kappa-B |
Target Info |
Activator |
[1]
|
KEGG Pathway
|
MAPK signaling pathway
|
NF-kappa B signaling pathway
|
Osteoclast differentiation
|
Legionellosis
|
HTLV-I infection
|
Epstein-Barr virus infection
|
Pathways in cancer
|
Viral carcinogenesis
|
NetPath Pathway
|
IL5 Signaling Pathway
|
PANTHER Pathway
|
Apoptosis signaling pathway
|
B cell activation
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
T cell activation
|
Toll receptor signaling pathway
|
Pathway Interaction Database
|
IL12-mediated signaling events
|
Alternative NF-kappaB pathway
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
Reactome
|
RIP-mediated NFkB activation via ZBP1
|
DEx/H-box helicases activate type I IFN and inflammatory cytokines production
|
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
Interleukin-1 processing
|
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
|
IkBA variant leads to EDA-ID
|
Dectin-1 mediated noncanonical NF-kB signaling
|
NIK-->noncanonical NF-kB signaling
|
TRAF6 mediated NF-kB activation
|
WikiPathways
|
Toll-like receptor signaling pathway
|
DNA Damage Response (only ATM dependent)
|
SIDS Susceptibility Pathways
|
Nuclear Receptors Meta-Pathway
|
Cytosolic sensors of pathogen-associated DNA
|
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
EBV LMP1 signaling
|
TNF alpha Signaling Pathway
|
TSLP Signaling Pathway
|
Neural Crest Differentiation
|
TWEAK Signaling Pathway
|
RANKL/RANK Signaling Pathway
|
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
|
Interleukin-1 processing
|
Folate Metabolism
|
Vitamin B12 Metabolism
|
Selenium Micronutrient Network
|
Regulation of toll-like receptor signaling pathway
|
References |
REF 1 | Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. |